How Does Merck Use siRNA Screens to ID Drug-Enhancing Genes? | GenomeWeb
Name: Steven Bartz
 
Position: Research fellow, cancer biology/molecular profiling, Merck Research Laboratories
 
Background: Senior research biologist, Merck Research Laboratories — 2001-2004
Postdoc, Fred Hutchinson Cancer Research Center — 1995-2001
PhD, medical microbiology and immunology, University of Wisconsin, Madison — 1995
BSc, microbiology, University of Wisconsin, La Crosse — 1989
 

 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.